Jul 2, 2026 08:30AM
Jul 2, 2026 08:30AM
Jun 16, 2026 08:02AM
Jun 16, 2026 08:00AM
Jun 2, 2026 08:01AM
Jun 2, 2026 08:00AM
May 14, 2026 08:03AM Cingulate reports Q1 2026 results, raises $14.9M in cash
May 14, 2026 08:00AM
Mar 18, 2026 08:00AM
Feb 17, 2026 08:02AM
Feb 17, 2026 08:00AM
Nov 13, 2025 08:00AM
Nov 10, 2025 08:01AM
Nov 10, 2025 08:00AM Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301
Oct 28, 2025 08:01AM
Oct 28, 2025 08:00AM
Oct 23, 2025 04:45PM
Oct 14, 2025 08:04AM
Oct 14, 2025 08:00AM
Sep 17, 2025 08:45AM
Sep 17, 2025 08:45AM Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment
Aug 19, 2025 08:45AM
Aug 15, 2025 09:02AM
Aug 15, 2025 09:00AM
Aug 6, 2025 08:45AM
Aug 6, 2025 08:45AM
Jul 29, 2025 08:01AM
Jul 29, 2025 08:00AM Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing for Marketing Approval of Lead ADHD Asset CTx-1301
Jul 9, 2025 08:03AM
Jul 9, 2025 08:00AM
May 20, 2025 08:03AM
May 20, 2025 08:00AM
May 14, 2025 08:04AM
May 14, 2025 08:00AM
May 8, 2025 04:30PM Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets
Apr 29, 2025 08:00AM
Apr 3, 2025 08:06AM
Apr 3, 2025 08:00AM
Mar 26, 2025 05:00PM
Mar 4, 2025 09:02AM
Mar 4, 2025 09:00AM
Jan 7, 2025 07:30AM Final Study Completed for Cingulate’s Lead Asset CTx-1301
Dec 23, 2024 07:30AM
Nov 7, 2024 07:30AM
Sep 12, 2024 08:30AM
Aug 15, 2024 07:45AM
Aug 15, 2024 07:45AM
Aug 13, 2024 07:45AM
Jun 25, 2024 09:20AM Cingulate (CING) Achieves Key Manufacturing Milestone in the Development of CTx-1301
Jun 25, 2024 09:20AM

326,557 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All